SG11201908788YA - Combinations of chk1- and wee1 - inhibitors - Google Patents
Combinations of chk1- and wee1 - inhibitorsInfo
- Publication number
- SG11201908788YA SG11201908788YA SG11201908788YA SG11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- cascadian
- seattle
- ave
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 abstract 2
- 229950009557 adavosertib Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 101150006084 CHKB gene Proteins 0.000 abstract 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480101P | 2017-03-31 | 2017-03-31 | |
| PCT/US2018/025464 WO2018183891A1 (en) | 2017-03-31 | 2018-03-30 | Combinations of chk1- and wee1 - inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908788YA true SG11201908788YA (en) | 2019-10-30 |
Family
ID=62002508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908788Y SG11201908788YA (en) | 2017-03-31 | 2018-03-30 | Combinations of chk1- and wee1 - inhibitors |
Country Status (11)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299493B2 (en) | 2017-10-09 | 2022-04-12 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| US12318452B2 (en) | 2018-09-27 | 2025-06-03 | Dana-Farber Cancer Institute, Inc. | Degraders of WEE1 kinase |
| CN113939296A (zh) | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| BR112022007609A2 (pt) * | 2019-10-25 | 2022-07-19 | Astrazeneca Ab | Métodos para tratar o câncer |
| CA3151403A1 (en) * | 2020-02-27 | 2021-09-02 | National University Corporation Hokkaido University | Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| CN115778962B (zh) * | 2022-11-28 | 2024-09-17 | 中国医学科学院肿瘤医院 | 治疗男性食管癌患者的药物及其相关应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003010444A1 (en) | 2001-07-23 | 2003-02-06 | Shock-Proof Solutions Pty Ltd | Mechanical shock absorbing apparatus |
| WO2005009435A1 (en) | 2003-07-25 | 2005-02-03 | Pfizer Inc. | Aminopyrazole compounds and use as chk1 inhibitors |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| AU2005270102A1 (en) | 2004-07-02 | 2006-02-09 | Icos Corporation | Compounds useful for inhibiting Chk1 |
| US20080318974A1 (en) | 2004-08-19 | 2008-12-25 | Icos Corporation | Compounds Useful for Inhibiting Chk1 |
| RS51616B (en) * | 2005-03-29 | 2011-08-31 | Icos Corporation | HETEROARYL UREE DERIVATIVES USEFUL TO INHIBIT CHK1 |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| MX2009010047A (es) | 2007-03-20 | 2009-12-04 | Smithkline Beecham Corp | Compuestos quimicos. |
| KR20100024932A (ko) | 2007-06-15 | 2010-03-08 | 반유 세이야꾸 가부시끼가이샤 | 비사이클로아닐린 유도체 |
| PA8850801A1 (es) | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| AU2010218781A1 (en) | 2009-02-25 | 2011-07-28 | Msd K.K. | Pyrimidopyrimidoindazole derivative |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| WO2013013031A1 (en) | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| ES2606640T3 (es) | 2012-02-23 | 2017-03-24 | Abbvie Inc. | Inhibidores de cinasas de tipo piridopirimidinona |
| KR102090792B1 (ko) * | 2012-05-15 | 2020-03-18 | 캔써 리서치 테크놀로지 리미티드 | 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201316024D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| WO2017216559A1 (en) | 2016-06-14 | 2017-12-21 | Almac Diagnostics Limited | Predicting responsiveness to therapy in prostate cancer |
| GB201612095D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-03-30 AU AU2018243667A patent/AU2018243667A1/en not_active Abandoned
- 2018-03-30 JP JP2019553068A patent/JP2020512977A/ja active Pending
- 2018-03-30 SG SG11201908788Y patent/SG11201908788YA/en unknown
- 2018-03-30 EP EP18718379.3A patent/EP3600247A1/en not_active Withdrawn
- 2018-03-30 CN CN201880032164.9A patent/CN110678169A/zh active Pending
- 2018-03-30 MX MX2019011506A patent/MX2019011506A/es unknown
- 2018-03-30 KR KR1020197031509A patent/KR20190130621A/ko not_active Ceased
- 2018-03-30 CA CA3058457A patent/CA3058457A1/en not_active Abandoned
- 2018-03-30 WO PCT/US2018/025464 patent/WO2018183891A1/en active Application Filing
- 2018-03-30 US US16/498,351 patent/US20200108074A1/en not_active Abandoned
-
2019
- 2019-09-17 IL IL26940919A patent/IL269409A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3600247A1 (en) | 2020-02-05 |
| IL269409A (en) | 2019-11-28 |
| KR20190130621A (ko) | 2019-11-22 |
| WO2018183891A1 (en) | 2018-10-04 |
| US20200108074A1 (en) | 2020-04-09 |
| AU2018243667A1 (en) | 2019-10-17 |
| CN110678169A (zh) | 2020-01-10 |
| CA3058457A1 (en) | 2018-10-04 |
| MX2019011506A (es) | 2019-11-01 |
| JP2020512977A (ja) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908788YA (en) | Combinations of chk1- and wee1 - inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201909676WA (en) | Treatment of her2 positive cancers | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |